Litigation Details for Takeda Pharmaceutical Company Limited v. Mylan, Inc. (S.D.N.Y. 2012)

« Back to Dashboard

Takeda Pharmaceutical Company Limited v. Mylan, Inc. (S.D.N.Y. 2012)

Docket		Date Filed	2012-03-20
Court	District Court, S.D. New York	Date Terminated	2014-04-17
Cause	M 22-1 Designation by U.S. Attorney of individual to accept service of summons and complaint	Assigned To	Denise Cote
Jury Demand	None	Referred To
Patents	6,099,859; 6,166,043; 6,172,090; 6,790,459; 6,866,866; 7,785,627; 7,959,946
Link to Docket	External link to docket

Details for Takeda Pharmaceutical Company Limited v. Mylan, Inc. (S.D.N.Y. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-03-20				External link to document

Takeda Pharmaceutical Company Limited v. Mylan, Inc. | 1:12-cv-02038: Litigation Summary and Patent Analysis

Last updated: August 29, 2026

Takeda Pharmaceutical Company Limited’s litigation against Mylan concerned generic colchicine tablets marketed as Colcrys. The case focused on U.S. Patent No. 7,582,621, which claimed low-dose colchicine treatment regimens for acute gout flares. The U.S. District Court for the District of Delaware held the asserted claims invalid for obviousness, and the Federal Circuit affirmed. The decision removed a principal patent barrier to generic colchicine entry and limited the commercial value of Takeda’s method-of-use patent estate.

What drug and patents were involved in Takeda v. Mylan?

The case involved Colcrys, Takeda’s 0.6 mg colchicine tablet. Colchicine is used to treat and prevent gout flares and to treat familial Mediterranean fever.

Item	Details
Branded product	Colcrys
Active ingredient	Colchicine
Dosage form	0.6 mg oral tablet
Plaintiff	Takeda Pharmaceutical Company Limited
Defendant	Mylan, Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:12-cv-02038
Primary patent	U.S. Patent No. 7,582,621
Patent technology	Low-dose colchicine treatment regimen
Statutory basis	Hatch-Waxman ANDA litigation
Final outcome	Asserted claims held invalid as obvious
Appellate result	Federal Circuit affirmed

Takeda sued after Mylan filed an abbreviated new drug application seeking approval to market a generic colchicine product. The complaint alleged infringement under 35 U.S.C. § 271(e)(2), which treats the filing of an ANDA containing a Paragraph IV certification as an artificial act of patent infringement.

What patent protected Colcrys in the Mylan litigation?

The central patent was U.S. Patent No. 7,582,621, generally referred to as the ’621 patent. The patent claimed methods of administering colchicine at a lower dose than traditional regimens, including an initial dose followed by a lower subsequent dose for acute gout treatment.

The patent was directed to a dosing method rather than a new colchicine molecule. Colchicine itself is an old natural product with a long history of medical use. Takeda’s patent position depended on whether the claimed regimen was sufficiently different from the prior art to satisfy the nonobviousness requirement of 35 U.S.C. § 103.

The litigation therefore did not primarily concern:

• The chemical composition of colchicine.
• A new crystalline form of colchicine.
• A new tablet manufacturing process.
• A biologic product or biosimilar pathway.
• A novel active pharmaceutical ingredient.

The dispute centered on dose selection, treatment sequencing, and the clinical advantages asserted for the low-dose regimen.

When did the Takeda v. Mylan litigation begin and end?

Takeda filed the action in 2012 in the District of Delaware. The case proceeded through claim construction, dispositive motions, and appellate review.

Key procedural timeline

Date	Event
2012	Takeda filed the Hatch-Waxman action against Mylan
2014	The District of Delaware issued its decision holding the asserted claims invalid for obviousness
2015	The Federal Circuit reviewed related Colcrys patent litigation involving the same patent estate
2016	The Federal Circuit affirmed the invalidity ruling in Takeda Pharmaceutical Co. v. Mylan Pharmaceuticals Inc., 835 F.3d 1331
After appeal	The invalidity judgment eliminated the asserted patent as a barrier to Mylan’s proposed generic product

The Federal Circuit’s decision was legally significant because it confirmed that the asserted low-dose colchicine regimen could not be protected merely by selecting a lower dose from a known therapeutic range where the prior art provided a reason to make that selection.

Why did the court find the colchicine patent obvious?

The court’s obviousness analysis focused on whether a person skilled in the art would have been motivated to develop the claimed low-dose regimen and would have had a reasonable expectation of success.

The relevant prior art described colchicine’s use for acute gout and addressed dosing, toxicity, tolerability, and treatment response. Takeda argued that the claimed regimen produced unexpected clinical benefits, including reduced gastrointestinal toxicity and an improved therapeutic profile.

The court rejected the argument that these results saved the claims from obviousness. The analysis treated the claimed regimen as an optimization of known colchicine therapy rather than an inventive departure from the prior art.

The Federal Circuit affirmed the district court’s conclusion. The decision applied established principles that:

1. Selecting a dose within a known therapeutic range can be obvious.
2. A claimed treatment regimen may be obvious even if clinical testing is needed to confirm the precise result.
3. Evidence of reduced toxicity or improved tolerability must be tied to the full scope of the claims.
4. Commercial success has limited weight when the commercial product includes unclaimed features or when market demand does not establish a nexus to the patented feature.

The outcome reflected the vulnerability of method-of-use patents that claim dose optimization for an old active ingredient.

What was the Paragraph IV issue in this case?

Mylan’s ANDA filing apparently included a Paragraph IV certification against Takeda’s listed patent. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Under the Hatch-Waxman framework:

• Takeda’s lawsuit triggered the statutory stay of FDA approval.
• The litigation tested the validity and potential infringement of the ’621 patent.
• A judgment of invalidity removed the patent-based obstacle to approval.
• Mylan did not need to wait for the patent’s nominal expiration date if the relevant patent claims were invalidated.

The case illustrates the commercial importance of Paragraph IV litigation. A successful invalidity judgment can accelerate generic entry by years, particularly where the challenged patent covers a dosing method with a later expiration date than the underlying drug product.

What was the Orange Book status of Colcrys?

Colcrys was listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The listed patent estate included method-of-use protection associated with colchicine treatment.

The Orange Book listing did not establish that the patent was valid. It identified patents that Takeda represented as covering the approved product or an approved use. Mylan’s Paragraph IV certification placed validity and infringement directly before the court.

Orange Book and regulatory implications

The case involved an ANDA for a generic immediate-release colchicine tablet. It was not a 505(b)(2) dispute and did not involve a biologics license application.

The principal regulatory consequences were:

• The FDA could consider approval after resolution of the patent litigation and statutory stay.
• The court’s invalidity judgment weakened the Orange Book patent barrier.
• Generic manufacturers could pursue approval for colchicine tablets without relying on a biosimilar pathway.
• The dispute did not require interchangeability litigation because colchicine is a small-molecule drug.

FDA approval and commercial launch remained separate from the court’s patent judgment. A generic company still had to satisfy FDA requirements concerning chemistry, manufacturing, controls, bioequivalence, labeling, and facility compliance.

Did the case involve formulation patents or manufacturing patents?

The reported litigation was principally a method-of-use dispute. The asserted patent did not create broad composition-of-matter protection for colchicine.

Formulation protection

The case did not establish a durable formulation monopoly over all colchicine tablets. A formulation patent could have protected matters such as:

• Tablet composition.
• Excipients.
• Dissolution profile.
• Stability.
• Modified release.
• Particle size or solid-state form.

Those issues were not the basis of the principal invalidity ruling in this action.

Manufacturing and process protection

The action also did not create a broad manufacturing barrier. Generic colchicine manufacturers could develop their own manufacturing processes, subject to FDA requirements and any separately enforceable process patent.

This distinction reduced the scope of Takeda’s post-judgment protection. The invalidity ruling affected the claimed regimen, while other patents, regulatory exclusivities, or confidential manufacturing know-how would have required separate analysis.

What was the litigation outcome?

The District of Delaware held the asserted claims of the ’621 patent invalid for obviousness. The Federal Circuit affirmed the judgment in 2016. The appellate ruling was the controlling disposition of the patent dispute.

Legal result

Issue	Result
Patent validity	Asserted claims invalid under 35 U.S.C. § 103
Infringement	No enforceable asserted claims remained to block Mylan on the invalidated patent
Enforceability	No separate enforceability ruling was required to produce the commercial result
Injunction	No lasting patent injunction against generic entry
Appeal	District court invalidity judgment affirmed
Settlement	The reported appellate outcome was a merits invalidity judgment, not a publicly controlling settlement resolution

The case is important because it did not merely produce a narrow claim-construction ruling. It invalidated the central patent protection asserted against Mylan.

Which companies were challenging Colcrys exclusivity?

Colcrys faced competitive pressure from multiple generic colchicine manufacturers. Colchicine is an established active ingredient, and the commercial opportunity extended beyond Mylan.

The competitive field included manufacturers pursuing ANDA approval for 0.6 mg colchicine tablets. Generic competition was shaped by:

• The invalidity of the ’621 patent claims.
• Other Orange Book-listed patents, if any remained enforceable.
• FDA approval timing.
• State substitution rules.
• Wholesale acquisition pricing.
• Pharmacy benefit manager formulary placement.
• Supply and manufacturing capacity.

Because colchicine is an old active ingredient, its generic market was more exposed to price competition than a market protected by composition-of-matter exclusivity.

How strong was Takeda’s Colcrys patent estate?

Takeda’s estate was stronger as a regulatory and method-of-use strategy than as a broad molecular patent estate.

Strengths

• Colcrys had an FDA-approved indication supported by clinical data.
• The low-dose regimen had commercial and clinical relevance.
• The Orange Book listing created a clear Hatch-Waxman litigation pathway.
• Method-of-use claims could delay approval while litigation was pending.
• The branded product had an established market and physician familiarity.

Weaknesses

• Colchicine was an old active ingredient.
• The asserted claims were vulnerable to prior-art dosing disclosures.
• Dose optimization is frequently challenged under obviousness law.
• The patent did not provide broad composition-of-matter protection.
• Clinical advantages had to show a nexus to the claimed regimen.
• Invalidity eliminated the principal litigation barrier against Mylan.

On balance, the patent estate had meaningful short-term blocking value but limited long-term durability after the obviousness ruling.

What generic entry risks existed for Colcrys?

The principal risk was an accelerated generic launch following invalidation of the ’621 patent.

Generic launch scenarios

Scenario	Commercial effect
Patent upheld	Generic approval or launch could be delayed until patent expiry or settlement date
Patent invalidated	FDA approval could proceed without waiting for patent expiration
Noninfringement finding	Mylan could launch without infringing the asserted claims
Settlement	Entry date would depend on the negotiated license and any authorized-generic terms
Additional patent barrier	Launch could remain delayed if another valid and enforceable Orange Book patent covered the product or use

The invalidity judgment materially increased generic-entry risk. It also reduced Takeda’s leverage in negotiations with other ANDA filers because the same patent could be attacked using similar prior art and obviousness arguments.

Did the case involve biosimilar risk?

No. The product was a small-molecule colchicine tablet regulated under the ANDA pathway. Biosimilar provisions under the Biologics Price Competition and Innovation Act did not apply.

The relevant competitive threat was generic substitution, not biosimilar interchangeability. That distinction matters commercially because generic approval can rely on pharmaceutical equivalence and bioequivalence rather than the more complex comparability and interchangeability framework applicable to biologics.

What was the revenue exposure from the litigation?

The litigation placed Colcrys revenue at risk from generic substitution and price erosion. Exact exposure depended on Takeda’s reported product sales, the number of approved generic applicants, launch timing, payer substitution, and any authorized-generic strategy.

The economic risk was asymmetric:

• Before generic entry, Colcrys could preserve branded pricing and formulary position.
• After generic entry, pharmacy substitution could rapidly shift volume away from the brand.
• Invalidation of a core method-of-use patent reduced Takeda’s ability to negotiate delayed entry.
• A broad generic launch could produce both volume loss and net-price compression.
• Remaining differentiation would depend on supply reliability, contracting, patient support, and prescribing habits rather than strong patent exclusion.

Because colchicine is an established oral tablet with a readily substitutable generic presentation, the commercial exposure was greater than for a complex formulation or biologic.

What licensing or settlement agreement affected the case?

The reported appellate disposition is a merits ruling affirming invalidity. The public case outcome is therefore analyzed as a patent invalidity judgment rather than as a settlement-controlled entry date.

A settlement would have been commercially relevant if it granted Mylan a licensed future-entry date, authorized-generic rights, or other consideration. The reported decision in 835 F.3d 1331 does not establish such a settlement as the basis for resolving the appeal.

What does the case mean for generic drug litigation?

Takeda v. Mylan demonstrates the limits of patent protection for dose-regimen innovations involving an old drug.

For branded companies, the decision highlights the need to:

• Generate prior-art searches focused on dose selection and treatment sequencing.
• Draft claims that capture clinically meaningful distinctions.
• Establish a strong nexus between unexpected results and claim scope.
• Pursue formulation, manufacturing, and patient-population claims where legally supportable.
• Avoid reliance on a single method-of-use patent for commercial protection.

For generic companies, the decision supports an invalidity strategy based on:

• Known therapeutic use.
• Prior-art dosing instructions.
• Toxicity and tolerability concerns.
• Routine clinical optimization.
• Lack of unexpected results across the full claim scope.

Key Takeaways

• Takeda sued Mylan over an ANDA for generic colchicine tablets related to Colcrys.
• U.S. Patent No. 7,582,621 was the principal patent at issue.
• The District of Delaware found the asserted claims obvious.
• The Federal Circuit affirmed in 2016 in Takeda Pharmaceutical Co. v. Mylan Pharmaceuticals Inc., 835 F.3d 1331.
• The patent protected a dosing regimen, not the colchicine molecule itself.
• The judgment increased the risk of generic entry and Colcrys price erosion.
• The dispute involved an ANDA and Paragraph IV certification, not a biosimilar application.
• The case reduced the blocking value of Takeda’s method-of-use patent estate.
• The public appellate outcome was a merits invalidity judgment rather than a settlement-based entry determination.

FAQs

What was the patent number in Takeda v. Mylan involving Colcrys?

The principal patent was U.S. Patent No. 7,582,621, which covered low-dose colchicine treatment regimens.

Did Mylan win the Colcrys patent litigation?

Yes. Mylan prevailed on the central validity issue after the district court held the asserted claims obvious. The Federal Circuit affirmed.

Was Colcrys protected by a composition-of-matter patent?

The litigation did not concern a new composition-of-matter patent for colchicine. Colchicine is an old active ingredient, and Takeda relied primarily on method-of-use protection for the low-dose regimen.

Was the Colcrys case a Paragraph IV lawsuit?

Yes. It was Hatch-Waxman ANDA litigation triggered by Mylan’s Paragraph IV challenge to Takeda’s listed patent.

Does Takeda v. Mylan affect generic colchicine products today?

The ruling weakened the patent barrier created by the ’621 patent and supported the ability of ANDA applicants to pursue generic colchicine approval without waiting for that patent’s nominal expiration.

References

1. U.S. Court of Appeals for the Federal Circuit. (2016). Takeda Pharmaceutical Co. v. Mylan Pharmaceuticals Inc., 835 F.3d 1331.

2. U.S. District Court for the District of Delaware. (2014). Takeda Pharmaceutical Company Limited v. Mylan, Inc., No. 1:12-cv-02038.

3. U.S. Patent and Trademark Office. (2009). U.S. Patent No. 7,582,621: Methods for treating gout and familial Mediterranean fever using low doses of colchicine.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

5. U.S. Food and Drug Administration. (n.d.). Colcrys (colchicine) prescribing information.